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ABSTRACT: Two efficient enzyme conjugation techniques have been explored by 
exploiting the reactions of bromomaleimides. The conjugations utilize monobromo- 
and dibromo- maleimides, which have been reacted with reduced disulfide bonds or 
terminal amines in α-chymotrypsin and human lysozyme. These reactions allow the 
formation of dithio- (DTM), monoamino- (MAM), and aminobromo- (ABM) 
maleimides, which are solvent-dependent fluorophores and have a handle for further 
functionalization, which allowed fluorogenic PEGylation via this technique. In this 
work, the efficiency of these maleimide conjugations was monitored and the 
fluorescence of the resulting conjugates have been examined. The quantum yields of 
the small molecule maleimide conjugates have been calculated, but are low due to 
solvent quenching effects. Catalytic activities of the conjugate enzymes have been 
compared to their respective native enzymes, which show no discernible effect of the 
modifications on enzymatic activity or stability at room temperature.  
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INTRODUCTION 
Fluorescent labelling of proteins is a widespread practice. It is used for many 
applications, including visualizing intracellular trafficking,(1) tracking cellular 
uptake,(2,3) measuring conformational changes,(4–6) and environmental sensing.(7) 
Commonly this is achieved by conjugating fluorescent proteins to the target.(8) Not 
only may the large size of such proteins have a significant effect on the 
properties/function of the target, but they are prone to photobleaching.(9,10) 
Another strategy is to conjugate a small molecule fluorophore to the studied protein 
via an amino acid residue.(11,12) Often this is achieved though the complex process 
of incorporating a non-natural amino acid into the protein through genetic 
expression, which can be selectively conjugated.(13–15) In unmodified enzymes the 
two most commonly accessed sites for labelling are lysine and cysteine residues, 
which can be utilized if minimal site specificity is required.(16) 
In addition to fluorescent labelling, conjugation to enzymes is frequently 
utilized for the attachment of poly(ethylene glycol) (PEG) to therapeutic targets, called 
PEGylation. PEGylation can enhance the therapeutic properties of a molecule. This 
can include better physical and thermal stability,(17) protection against 
degradation,(18) increased solubility,(19) longer half-life in vivo,(20) and even 
increased potency.(21) As of 2013, there were nine PEGylated proteins approved by 
the FDA for pharmaceutical use.(22) All of these are conjugated via either lysine 
residues, the N-terminus or cysteine residues.(22)  
Cysteine is regarded as the most nucleophilic amino acid in the majority of 
proteins and therefore is commonly regarded as the easiest to modify. The most 
widely used cysteine modification technique is maleimide conjugation; in which 
cysteine will undergo a highly selective addition to the maleimide double bond.(23,24) 
This technique has been utilized for the creation of responsive polymer-protein 
bioconjugates,(25) for PEGylation,(26) target specific fluorescent labelling,(27) and 
the radiolabeling of proteins.(28) In recent literature, it has been shown that 
monobromomaleimides (MBM) and dibromomaleimides (DBM) also undergo efficient, 
selective reactions with cysteine residues.(29,30) In comparison to maleimide 
conjugations, the double bond of the maleimide is retained and hence the reaction 
is reversible. This has led to applications in antibody conjugations, where the 
reaction of two reduced cysteines with dibromomaleimide forms a bridged 
dithiomaleimide (DTM) conjugate. (31–33) The bridging of disulfides using DBMs has 
been optimized to provide a high yielding, site-selective method for drug-antibody 
conjugation, allowing control over drug loading. By linking trastuzumab with 
antibody monomethyl auristatin E via a DTM linker, Nunes et. al. synthesized an 
antibody-drug conjugate (ADC), which showed cancer cell selectivity and excellent 
potency in vitro.(34) Haddleton and co-workers have applied this technique to salmon 
calcitonin, a small helical peptide,(35) and oxytocin, a therapeutic cyclic peptide 
which helps reduce postpartum hemorrhaging.(36,37) When PEG is conjugated to 
oxytocin using this technique, the solution stability of the peptide was greatly 
improved, however effects on in vivo activity have not been reported. The technique 
has also recently been reported as a peptide stapling method to stabilize α-helices 
and help prevent proteolysis.(38) 
 In addition to their use in disulfide bridging, DTMs have been proven to be a 
class of highly emissive fluorophore.(35) It has been shown that the solubility and 
further functionalization of DTMs could be easily varied through selection of N- and 
S- substituents. Generally, the fluorophore has bright solvent-dependent emission, 
around 500 nm in dioxane, with polar protic solvents causing a red shift and 
quenching of emission. The fluorescence has also been demonstrated to be quenched 
by aromatic thiol substitution (e.g. dithiophenolmaleimide).(39) The dye has found 
applications in polymer research after the supramolecular assembly of DTM-
functionalized polymers was shown to dictate emissivity, emission polarization, and 
fluorescence lifetime.(35,39–43) This has been attributed to the polymeric scaffold 
preventing both solvent and collisional quenching effects. In vivo studies of DTM 
polymers enabled differentiation of the micellar and unimeric species, based on 
fluorescence lifetime imaging microscopy (FLIM), as a consequence of the shorter 
fluorescence lifetimes of the unimeric species.(39) The presence of a DTM dye also 
allows detection of guest molecules by Förster resonance energy transfer (FRET).(44) 
In the meantime, it has been shown that monoaminomaleimides (MAMs) and 
aminobromomaleimides (ABMs), which are synthesized by addition–elimination 
reactions with MBM and DBM respectively, are also highly emissive.(45) These 
moieties have large Stokes shifts (~100 nm) and show solvent-dependent emission 
wavelengths and intensities, with polar protic solvents causing a red shift and large 
reduction in emission intensity. In parallel to DTMs, they are also quenched by direct 
conjugation of aromatic amines to the maleimide ring, but these 
arylaminomaleimides have been shown to exhibit aggregation induced fluorescence 
in the solid state.(46,47) We proposed, based on bromomaleimide conjugations with 
cysteine, that a conjugation induced fluorescence technique could be realized 
utilizing lysine residues. Amine-reactive conjugation techniques are often used for 
conjugations, most frequently through N-hydroxysuccinimide (NHS) activated esters 
or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling.(16,48) These 
techniques require activation of a carboxylic acid group prior to conjugation through 
additives, and as a result of the large number of lysine residues usually present in 
proteins, it is typically difficult to control the location and number of 
modifications.(48) A fluorogenic technique that is high yielding and requires no 
additives or activation, could offer an attractive alternative approach to the 
conjugation of large fluorescent dyes or fluorescent proteins as used in many current 
applications,(49) and would provide a fluorogenic PEGylation method.  
In addition to their fluorescence properties, it is important to consider the 
effect of bromomaleimide conjugations on protein structure and enzymatic function. 
In previous research DTMs have not been conjugated specifically to functional 
enzymes, but they have been conjugated to peptides, for example salmon 
calcitonin(50) and oxytocin(36,37) however, the effect on activity of these peptides 
has not been studied. Therefore, it is unknown whether the initial activity or long 
term stability of a therapeutic peptides or an enzyme would be impacted through the 
introduction of these moieties upon conjugation. It is hypothesized that the bridging 
of disulfide bonds with a maleimide moiety could introduce additional stability, 
through preventing disulfide reduction. This study will investigate the formation of 
functionalized MAMs, ABMs and DTMs in enzyme conjugations and how the 
substituents affect the integrity of two enzymes, α-chymotrypsin (α-CT) and human 
lysozyme (HLZ), which are enzymes commonly used in conjugation based 
applications and have been extensively characterized.(51–58) 
 
MATERIALS AND METHODS 
α-chymotrypsin (Type II from bovine pancreas, lyophilized powder) and 
human lysozyme (expressed in rice, lyophilized powder) were used as received from 
Sigma-Aldrich and stored in a freezer at approximately -18 C. All other chemicals 
were obtained from either: Sigma Aldrich, Fisher Chemicals, Acros Chemicals, Alfa 
Aesar or IRIS biotech GmbH and used as received.  
2-3-dibromo-pyrrole-2,5-dionefunctionalized PEG350 (1)  
Triphenyl phosphine (1.44 g, 5.5 mmol) was dissolved in dry tetrahydrofuran 
(100 mL) and cooled to -78 °C. Diisopropyl azodicarboxylate (1.14 mL, 5.5 mmol) was 
added dropwise and the solution was left to stir for 5 minutes. Methoxypoly(ethylene 
glycol) (Mn= 350 g/mol, 1.75 g, 5.5 mmol) was added dropwise to the cooled solution 
and left to stir for a further 5 minutes. Neopentyl alcohol (0.22 g, 2.5 mmol) was 
added and left to stir for a further 10 minutes. 3,4-dibromomaleimide (1.39 g, 5.5 
mmol) was added to the solution and left to stir at -78 °C for 1 hour. The solution 
was allowed to warm to room temperature and left to stir for 24 hours. The solvent 
was removed in vacuo, and the resultant oil purified by silica column by flash 
chromatography (2:1 to 0:1 gradient of petroleum ether 40-60°C : EtOAc) to yield a 
yellow oil 1 (287 mg, 17 %). Rf (2:1 petroleum ether 40-60°C : EtOAc): 0.1 to 0.4. 
1H NMR (CDCl3, 300MHz, ppm)- δ 3.82 (t, 3JH-H= 5.6Hz, 2H, NCH2), 3.71-3.53 (br m, 
31H, CH2-CH2), 3.38 (s, 3H, CH3-O). 
13C NMR (CDCl3, 125MHz) δ (ppm) = 163.8, 129.4, 71.9, 70.6-70.5, 70.1, 67.5, 59.0, 
38.9  
HR-MS (MaXis) - [M+Na]+ calculated m/z 688.0764, observed m/z 688.0768 
FTIR (cm-1) –2872 (υC-H), 1716 (υC=O), 1104 (υC-O) 
Synthesis of 3-bromo-1-methyl-1H-pyrrole-2,5-dione (2)  
The synthesis was based on a previously reported literature procedure.(59) To 
a solution of bromomaleic anhydride (1 g, 5.65 mmol) in acetic acid (20 mL) was 
added methyl amine in ethanol (695 µl, 5.65 mmol). The solution was refluxed for 3 
hours after which the solvent was removed in vacuo. The resultant solid was purified 
by silica column chromatography and eluted with 10% ethyl acetate in petroleum 
ether 40-60 °C to give a cream colored solid 2 (190 mg, 15 %). Rf : 0.2 
1H NMR (CDCl3, 500 MHz) δ (ppm) = 6.88 (s, 1H, CHCBr), 4.33 (s, 3H, NCH3). 
MS (ESI) - [M+H]+: observed: 190.0 calculated: 189.9 
Matches literature data.(59) 
Synthesis of 3-bromo-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-dione (3)  
The synthesis was based on a previously reported literature procedure.(59) To 
a solution of bromomaleic anhydride (1.2 g, 6.9 mmol) in acetic acid (15 mL) was 
added propargyl amine (432 µl, 7.5 mmol). The solution was refluxed for 6 hours 
after which the solvent was removed in vacuo. The resultant solid was purified by 
silica column chromatography and eluted with 100% dichloromethane (CH2Cl2) to 
give a cream colored solid 3 (1.1 g, 78 %). Rf (100% CH2Cl2): 0.9 
1H NMR (CDCl3, 300MHz) δ (ppm) = 6.39 (s, 1H, CHCBr), 4.33 (d, 4JH-H= 2.5Hz, 2H, 
NCH2) and 2.24 (t, 4JH-H= 2.5Hz, 1H, HC≡C). 
13C NMR (CDCl3, 75MHz) δ (ppm) = 167.1, 162.1, 132.2, 131.7, 76.4, 72.1 and 27.8. 
HR-MS (MaXis) - [M+Na]+ calculated m/z 235.9318, observed m/z 235.9316  
FTIR (cm-1) – 3271 (υH-C≡C), 1702 (υC=O), 1687 (υC=O). 
Elemental analysis found: C 39.23, H 1.80, N 6.48; expected (C7H4BrNO2): C 39.29, 
H 1.88, N 6.54. 
3-bromo-pyrrole-2,5-dionefunctionalized PEG800 (4) 
Methoxy-poly(ethylene glycol)-amine800 (Mn= 800 g/mol, 0.48g, 0.6 mmol) was 
added to 15ml of acetic acid. Bromomaleic anhydride (0.13 g, 0.75 mmol) was added 
and the solution was refluxed overnight. The solvent was removed in vacuo and the 
resultant orange oil purified by flash chromatography on a silica column (2:1 CH2Cl2 : 
Methanol) to give a viscous oil 4 that was >90 % functionalized according to 1H NMR 
spectroscopy (0.403 g, 67 %). Rf (2:1 CH2Cl2 : Methanol): 0.05-0.35. 
1H NMR (CDCl3, 300MHz)- δ (ppm) 6.88 (s, 0.9H, CHCBr), 3.77 (t, 3JH-H = 5.4Hz, 2H, 
NCH2), 3.68-3.53 (br m, 76H, CH2-CH2), 3.38 (s, 3H, CH3-O). 
13C NMR (CDCl3, 500MHz, ppm)-168.4, 156.2, 132.0, 131.4, 71.9, 70.6-70.5 (m), 
70.1, 67.7, 38.08  
HR-MS (MaXis) - [M+Na]+ calculated m/z 872.3250, observed m/z 872.3257 
FTIR (cm-1) – 2824 (υC-H), 1720 (υC=O), 1106 (υC-O) 
General procedure for dithiomaleimide conjugations 
3 mg of enzyme was dissolved in 1.3 mL 0.1 M pH 6 Phosphate buffer, followed 
by addition of 0.1 mL tris(2-carboxyethyl)phosphine (TCEP) solution (4 equivalents 
per disulfide, in 18.2 MΩ.cm water). The reaction was vortexed and left to stir for 30 
minutes. After this, 0.1 mL of DBM solution (5 equivalents per disulfide, in DMF) was 
added and the mixture vortexed. Maximum degree of conjugation, identified by 
MALDI-ToF MS, was reached after 30-60 minutes. The crude enzyme was purified 
by ultrafiltration (AMICON® stirred cell), freeze-dried and analyzed by MALDI-ToF. 
General procedure for aminomaleimide conjugations 
3 mg of enzyme was dissolved in 1 mL of 0.1 M pH 8.5 Tris buffer. 0.5 mL 
DBM solution (5 equivalents per amine in DMF) was added and the solution vortexed. 
Maximum degree of conjugation, identified by MALDI-ToF MS, was reached after 
leaving overnight. The crude enzyme was purified by ultrafiltration, freeze-dried and 
analyzed by MALDI-ToF. 
α-Chymotrypsin p-nitroaniline hydrolysis assay 
Activity and stability of the enzyme and conjugates were assessed by analysis 
of the initial velocity changes in absorbance with time. Native αCT and conjugates (2 
µg/ml) were incubated in 0.1 M sodium phosphate buffer (pH 6) at 4 °C. 20 μL 
aliquots of these solutions were added to 160 μL of 0.1M sodium phosphate buffer 
(pH 6) in a 96 well plate and 20 μL of N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide in 
methanol (3 mg/ml) was added. Each sample was run in triplicate against buffer 
blanks. The initial rate of hydrolysis of the substrate was monitored through 
recording the rate of increase in absorption at 405 nm at 25 °C over 30 minutes. 
Background hydrolysis was subtracted to give initial rates of hydrolysis. 
Human lysozyme EnzCheck® lysis assay 
Lysozyme assays were carried out as reported in the literature.(60) Lysozyme 
substrate stock suspension (1.0 mg/ml) was prepared according to the 
manufacturer, and aliquots were diluted to 50 mg/ml for each assay. Prior to 
conjugate analysis, the substrate was used to generate a standard curve. 6 wells of 
a 96 well plate were filled with 50 μL of 0.1 M sodium phosphate buffer (pH 6) 
followed by a solution of 50 μL 500 U/mL of human lysozyme solution was added to 
the first well. The solutions were mixed and 50 μL was transferred into a second well. 
This was repeated over 5 wells, with the final 50 μL from the 5th well discarded. To 
these solutions, 50 μL of the 50 mg/ml substrate solution was added. These 
solutions in triplicate were incubated at 37 °C in a plate reader and emission at 530 
nm (excitation at 492 nm) was recorded vs. time. From this, a value of 62.5 U/ml 
was identified as the concentration for future assays. For the stability assay, Native 
human lysozyme and conjugates (2 mg/ml) were incubated in 0.1 M sodium 
phosphate buffer (pH 6) at 4 °C. Aliquots of these solutions were diluted to 5 µg/ml 
and 50 μL of these solutions was pipetted onto a 96 well plate. To these solutions, 
50 μL of the 50 mg/ml substrate solution was added and these solutions, in 
triplicate, incubated at 37 °C in a plate reader. Analysis was carried out by measuring 
emission at 530 nm after 30 minutes, as per the manufacturer’s protocol. Errors 
were measured as a standard deviation over all time points for each triplicate.  
Quantum yield fluorescence analysis 
Quantum yield analysis was based on a previously reported literature 
procedure.(61) A solution of quinine sulfate dihydrate (15 µmol) in 0.105 M perchloric 
acid, was used a standard (Φquinine = 59 %), from which a UV-Vis spectrum was 
recorded. 
The conjugate of interest was diluted to a concentration affording an 
absorbance <0.1 at the excitation wavelength determined by UV-Vis analysis. Both 
spectra were overlaid, and the optimal excitation wavelength for the calculation was 
chosen to be the wavelength where the standard and the sample have the same 
absorption. Using the excitation wavelength for fluorescence, the emission of both 
samples was measured. To calculate the quantum yield Equation 1 is used, where 
F= Integral photon flux (emission integral), f= absorbance, n=refractive index of the 
solvent, 𝜆𝑒𝑚= emission wavelength, conj=conjugate sample, and st=quinine standard.   
Equation 1:  Φ𝑓,𝑐𝑜𝑛𝑗 =  Φ𝑓,𝑠𝑡 .
𝐹𝑐𝑜𝑛𝑗
𝐹𝑠𝑡
.
𝑓𝑠𝑡
𝑓𝑐𝑜𝑛𝑗
.
𝑛𝑐𝑜𝑛𝑗
2 (𝜆𝑒𝑚)
𝑛𝑠𝑡
2 (𝜆𝑒𝑚)
 
As the absorbance for the standard and sample match, it can be neglected 
(fst/fconj=1). Refractive indices are found for the conjugate and quinine solvents at 
their respective average emission wavelengths (wavelength corresponding to the 
mean of the emission spectrum integration). The standard quantum yield 
Φf,st(Φquinine= 59 %) was used to calculate the relative fluorescence of each conjugate.  
Instrumentation 
NMR spectra were recorded on a Bruker Avance 300, a Bruker Avance III HD 
400 or a Bruker Avance III HD 500 spectrometer at 298k and 300, 400 and 500 MHz 
respectively. Shifts are quoted in δ in parts per million and quoted relative to the 
internal standard trimethylsilane (TMS). High Resolution Mass Spectra (HR-MS) were 
conducted on a Bruker UHR-Q-ToF MaXis spectrometer with electrospray ionization. 
MALDI-ToF MS was conducted on a Bruker Autoflex MALDI TOF/TOF spectrometer. 
For MALDI analysis protein solution (2.0 mg/ml) was spotted on the MALDI plate 
followed by an equal volume of sinapinic acid matrix (15 mg in 0.5 mL of water, 0.5 
mL of acetonitrile and 1 μL of trifluoroacetic acid (TFA). The solvent was evaporated 
before the recording of spectra and analysis using FlexControl software. Gaussian 
fits were completed on aminomaleimide conjugates which could be successfully fitted 
and full width at half maximum (FWHM) analysis was used to determine the standard 
deviation (FWHM = 2.355*σ). It should be noted that MALDI-ToF MS analysis of 
native HLZ showed a strong signal at around 14110 m/z, which does not match 
literature structures of HLZ, but has been observed by other groups.(62) However, 
the secondary peak at 14692 m/z correlates well with published structures and 
therefore conjugation mass shifts were based on this value.  
Infrared spectra were recorded on neat samples using a Perkin Elmer 
Spectrum 100 FT-IR Spectrometer. UV-Vis spectroscopy was carried out on a Perkin 
Elmer Lambda 35 UV-Vis spectrometer or an Agilent Cary 60 UV-Vis Spectrometer 
at room temperature. Fluorescence spectra were recorded using an Agilent Cary 
Eclipse Fluorescence spectrophotometer. Quartz cells with four polished sides 
(Starna) were used for fluorescence and UV-Vis measurements. Enzyme assays were 
conducted on a FLUOstar OPTIMA multi-well microplate reader according to the 
assay conditions for each individual enzyme.  
Differential scanning calorimetry (DSC) analysis was performed on a TA 
instruments Nano DSC. Blank runs were ran with buffer in both sample and 
reference side. Each protein sample was run with buffer in the reference side. Scans 
were made between 20 and 100 °C at 1 °C/min and a 600 s equilibration time was 
applied prior to each the scan. Circular dichroism (CD) spectra were recorded on a 
J-720 CD spectrometer in 1 mM pH 6.0 phosphate buffer using a quartz cuvette with 
a path length of 0.1 cm. All experiments were run with ten acquisitions and recorded 
at 20 nm/min. The molar ellipticity was based off protein concentration measured at 
280 nm.  
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
To study disulfide re-bridging on enzymes the five disulfide bonds of α-CT were 
targeted as handles for conjugation. N-methyldibromomaleimide (M-DBM) was 
chosen as the initial conjugating molecule, due to its small size and reported 
resistance to hydrolysis,(44) and tris(2-carboxyethyl)phosphine (TCEP) was used to 
reduce the disulfides prior to conjugation (Figure 1A). Unusually for disulfide based 
conjugations, reacting M-DBM under an optimized protocol produced a singular 
conjugate with three DTMs conjugated (Figure 1C) as observed by matrix-assisted 
laser desorption/ionization-time of flight mass spectroscopy (MALDI-ToF MS). This 
suggests that two of the disulfides are not solvent accessible and therefore under 
such conditions this conjugation technique can produce site-specific conjugates.  
Figure 1: (A) Illustration of disulfide based bromomaleimide conjugations to α-CT 
and HLZ. (B) 2D excitation–emission spectra of M-DTM HLZ conjugate. MALDI-ToF 
mass spectra of (C) M-DTM α-CT conjugate (D) PEG-DTM α-CT conjugate (E) M-DTM 
HLZ conjugate (F) PEG-DTM HLZ conjugate (red) with the native enzyme (black). 
 
To confirm this, analysis of the availability of the disulfides in αCT was 
undertaken. Firstly, a Kyte-Doolittle plot was drafted to establish if any of the 
disulfides were located in a particularly hydrophobic location in the enzyme, which 
may be buried and therefore inaccessible for conjugation. (Figure S15). While the 
disulfide C168-C182 appears to be the most hydrophobic – and therefore least likely 
to be reacted - and disulfide C191-C220 appears to be the most hydrophilic, no other 
conclusions could be drawn. To gain further insight the solvent accessible surface 
area of the enzyme was calculated using a crystal structure of the enzyme (from the 
Protein Data Bank: 4CHA).(52) It was clear that C191-C220 had the most solvent 
accessible surface area (Table S1) by this model, and C168-C182 and C191-220 
displayed minimal to no solvent accessible surface area. This is in concurrence with 
the hydrophobicity plot, suggesting that the C1-C122 bond is very likely to be the 
most reactive disulfide, and that the C168-C182 and C191-220 bonds are the 
unmodified bonds. A trypsin digest was attempted to prove this hypothesis, however 
as a consequence of α-CT autolysis this was not informative. 
To ascertain that the bromomaleimide conjugations are applicable to a range 
of enzymes, human lysozyme was chosen as a second target for conjugation. Human 
lysozyme (HLZ) has four disulfide bonds as handles for attachment, is smaller than 
α-CT and does not perform autolysis.(54) Disulfide bridging to HLZ using M-DBM 
was undertaken using the same conditions as for α-CT. In contrast to α-CT, a 
distribution of 0-4 DTM species were observed by MALDI-ToF MS after purification 
(Figure 1E). Interestingly, up to four DTMs can be formed per enzyme suggesting that 
all are solvent accessible, which may be a result of the more hydrophilic nature of 
HLZ. However, as often observed in multi-site conjugation techniques,(57) only a 
distribution of differentially conjugated products was obtainable, indicating that the 
site-specific nature of this technique is limited.  
The retention of tertiary structure was probed through circular dichroism 
(CD). α-chymotrypsin exhibits a very poor CD signal for characterization in the amide 
region,(63) therefore CD analysis was undertaken on HLZ and the DTM HLZ 
conjugate. By recording Δ[Ɵ]m at 222 nm the α-helicity of the enzyme can be 
measured. A negligible reduction in [Ɵ]222 was noted for the conjugate (97% of the 
native HLZ – Figure S13) and both CD spectra showed very similar structural 
features, indicating minimal effect of conjugation on the tertiary structure of HLZ.  
For further characterization, the denaturing temperature (Tm) was measured 
for HLZ and the HLZ DTM conjugate for comparison, using differential scanning 
calorimetry. The Tm for the native enzyme was measured as 72.7 °C in pH 6 buffer, 
which compares well to previous literature.(64) For the HLZ DTM conjugate, multiple 
melts were observed (Figure S14), however the major melt can be attributed to the 
singular DTM HLZ conjugate and was measured at 68.2 °C, suggesting a small loss 
in thermal stability upon DTM conjugation. The unresolved melts observed below 
68.2 °C could be attributed to conjugates with more than one DTM. 
To establish whether this technique is suitable for PEGylation, one of the most 
commonly undertook conjugation procedures, PEG-dibromomaleimide (PEG-
DBM - 1) was synthesized for use as a conjugation agent. Conjugations were 
attempted in pH 6 sodium phosphate buffer with a range of DMF concentrations 
from 0-33% v/v. MALDI-ToF MS analysis for the conjugation of both enzymes to 
PEG-DBM (1) showed that higher DMF concentration lead to higher degrees of PEG 
conjugation. For α-CT conjugation, 33% v/v DMF conditions gave an average by 
Gaussian fit of 1.8 attached PEG-DTM molecules (Table 1). The HLZ conjugate 
however, was observed to have a broader MALDI-ToF mass spectra, where an average 
of 2.0 PEG-DTMs per enzyme was observed (Table 1). 
 
 
 
 
 
Table 1. Table showing number of attached units and conjugation efficiency for disulfide conjugates 
observed by MALDI-ToF and standard deviation measured by Gaussian fit. †= Gaussian fit not 
possible, observed conjugates listed. ‡= Quantification not possible. 
 
In order to ascertain whether the conjugated enzymes were fluorescent, 
excitation and emission spectra were measured for all conjugates of both α-CT and 
HLZ (for example M-DTM HLZ conjugate in Figure 1B). Table S2, highlights the 
excitation and emission maxima recorded for the synthesized conjugates (spectra are 
shown in supporting information 2.1). Emission wavelengths for all conjugates 
synthesized were similar to those observed in polar solvents for DTM small 
molecules. (45) 
Following this, conjugation utilizing lysine residues was investigated as a 
novel “turn-on” fluorescence conjugation method. Both enzymes are abundant in 
lysine residues, with α-CT containing seventeen amine handles for targeting, and 
HLZ six; this includes three N-terminal residues for α-CT and one for HLZ.(52,54) 
Using M-DBM the conditions of the conjugation were altered to mimic those in the 
synthesis of ABMs (Figure 2). Conjugating to α-CT overnight, in pH 8.5 buffer, results 
in a distribution of products as seen at around 26,600 m/z by MALDI-ToF MS (see 
supporting information 1.1.5). By completing a Gaussian fit of this peak an average 
of 6.2 ± 2.5 ABMs per enzyme is observed. By exposing human lysozyme to the same 
conditions, successful conjugation was observed by MALDI-ToF MS with an average 
of 2.7 ± 2.3 ABMs formed per enzyme from six amine handles (Table 2).  
Enzyme Conjugate # Attached 
Conjugation 
efficiency 
α-CT 
M-DTM 3/5† 60 % 
PEG-DTM 1.8 ± 1.5/5 36 % 
HLZ 
M-DTM  0-4/4†   ‡ 
PEG-DTM 2.0 ± 1.8/4 50 % 
The synthesis of smaller MAM dyes has also been reported under these 
conditions. It was, therefore, decided to synthesize methyl-MBM (2), alkyne-MBM (3) 
and PEG-MBM (4) for conjugation. The alkyne substituent provides an opportunity 
for further functionalization, for example via copper-catalyzed Huisgen 
cycloaddition.(25) Conjugation of 2 and 3 was successful for both enzymes and 
subsequent MALDI-ToF MS analysis showed a distribution of products. Gaussian 
fits of the spectra are listed in Table 2. The reaction proved much more effective than 
the ABM reactions showing conjugation of up to 12.1 ± 3.6 MAMs for the α-CT M-
MAM conjugate (Figure 2C). PEGylation using 4 was also successful, however lower 
reactivity was again observed with an average of 2.3 PEG units attached to α-CT and 
1.6 to HLZ. 
 
Figure 2: (A) Illustration of amine based bromomaleimide conjugations to α-CT and 
HLZ. (B) 2D excitation–emission spectra of alkyne-MAM HLZ conjugate. MALDI-ToF 
mass spectra of (C) alkyne-MAM α-CT conjugate (D) PEG-MAM α-CT conjugate (E) 
alkyne-MAM HLZ conjugate (F) PEG-MAM HLZ conjugate (red) and the native 
enzyme (black). 
 
 
 
 
 
 
 
 
Table 2. Table showing number of attached units and conjugation efficiency for amine conjugations 
observed by MALDI-ToF and standard deviation measured by Gaussian fit. 
Enzyme Conjugate # Attached 
Conjugation 
efficiency 
α-CT 
M-ABM 6.2 ± 2.5/17 36 % 
M-MAM 12.1 ± 3.6/17 71 % 
Alkyne-MAM 11.2 ± 1.8/17 66 % 
PEG-MAM 2.3 ± 1.5/17 14 % 
HLZ 
M-ABM 2.7 ± 2.3/6 45 % 
M-MAM 5.4 ± 3.1/6 90 % 
Alkyne-MAM 4.9 ± 2.5/6 82 % 
PEG-MAM 1.5 ± 1.8/6 25 % 
DTM conjugates have been shown to undergo hydrolysis at pH 8.5, dependent 
on structure, with half-lives as short as 16.5 minutes.(65) In order to ascertain the 
stability of MAM conjugates, the emission of alkyne-MAM HLZ was studied in pH 8.5 
buffer. Under these conditions no hydrolysis was observed over 10 hours (Figure 
S16), indicating greater resistance to hydrolysis in these MAM species.   
Excitation/emission spectra were again measured for all aminomaleimide 
conjugates of both α-CT and HLZ (for example alkyne-MAM HLZ conjugate in Figure 
2) and wavelengths recorded were similar to those observed in water for small 
molecule species.(45) Small molecule MAMs have been shown to exhibit high (>59 %) 
quantum yields in organic aprotic solvents, however, in water they are quenched 
significantly, exhibiting Φf<0.4 %.(45) Robin et al. have shown that by incorporating 
DTMs into nanostructures, shielding them from solvent quenching effects, the 
quantum yield can be restored (>30 %).(39) To investigate whether the same effect 
would be observed in enzymes, the quantum yield of two conjugates was calculated. 
The quantum yield of both alkyne-MAM and M-DTM HLZ conjugates was calculated 
in 18.2 MΩ.cm water, using a standard of quinine (Φquinine = 59 %). The alkyne-MAM 
HLZ conjugate exhibited a quantum yield of Φf(%)=0.7 ± 0.04 (λex=362 nm) and the 
M-DTM HLZ conjugate of Φf(%)=0.8 ± 0.07 (λex=365 nm). The quantum yields for both 
conjugates have increased compared to the DTM and MAM small molecule analogues 
in water (all less than 0.4 %),(45) however, the values were significantly lower than 
the fluorescent proteins currently used and would not meet the brightness 
requirements for applications such as fluorescence microscopy.(66) The quantum 
yield of the PEGylated HLZ samples were also calculated to compare to the small 
molecule analogues. The PEG-DTM HLZ conjugate exhibited a quantum yield of 
Φf(%)=0.5 ± 0.05 (λex=362 nm), lower than the respective M-DTM conjugate. This 
could be attributed to the lower degree of conjugation observed for the polymer 
species. Theoretically, the most accessible and least shielded disulfide would be the 
most likely to undergo conjugation, leading to high solvent accessibly, and therefore 
fluorescence quenching, of the resulting maleimide moiety. In contrast, the PEG-
MAM species exhibited a quantum yield of Φf(%)=1.4 ± 0.2 (λex=364 nm), double the 
quantum yield of the respective alkyne-MAM conjugate. In this case, despite 
exhibiting a lower degree of conjugation compared to the small molecule conjugate, 
it would appear the polymer chain provides a solvent shielding effect to the MAM dye.  
To establish the structural integrity and catalytic activity of the DTM and MAM 
α-CT conjugates, their activity was measured using a p-nitroaniline hydrolysis assay. 
The initial velocity was measured and compared to the native enzyme at time points. 
Results indicated a drop in activity after conjugation for all conjugates (Figure 3A). 
However it should be noted that the activity is comparable to that of native enzyme 
left in solution for the time period of the conjugation and purification (6 hours for the 
DTM conjugates and 24 hours for the MAM conjugates), indicating that the chemical 
modification itself has negligible effect on enzyme activity, which corroborates the 
CD analysis for the HLZ DTM conjugate. Positively, stability of the enzyme over 4 
days was unaffected (Figure 3B), suggesting the conjugates have similar stability and 
autolysis rate to the native enzyme.  
 
 
Figure 3: (A) Initial activity of α-CT at time points against purified conjugates at t = 
0 hr and (B) residual activities of native α-CT and conjugates (black = native 
enzyme; red = M-DTM conjugate; blue = alkyne-MAM conjugate; green = PEG-DTM 
conjugate; yellow = PEG-MAM conjugate). 
 
The HLZ conjugates were assayed by EnzChek® lysis to confirm their integrity. 
This assay relies on the lysis of fluorescein labelled micrococcus lysodeikticus cells, 
where upon cell lysis fluorescence signal increases.(60) When stored at room 
temperature the conjugates show no discernable difference in activity compared to 
native HLZ (Figure 4A). To discern whether any differences in stability are observed 
in more extreme conditions, the conjugates were also examined at 50 °C, and their 
activity was measured at various time intervals. It has been shown that under raised 
temperature storage, the stability of native HLZ is negatively affected.(55) Results 
showed that the MAM conjugates showed a decrease in activity over 7 days 
comparable to that of the native enzyme. On the other hand, the DTM conjugates 
exhibited a decrease in activity. Specifically, the M-DTM conjugate lost all activity 
over 9 days compared to the native enzyme which retained 44% activity (Figure 4B). 
This indicates that disulfide re-bridging negatively affected enzyme stability at raised 
temperature, with the M-DTM conjugate, having the most DTM bridged disulfides, 
being least stable.   
 
Figure 4: The residual activity, by EnzChek® lysis assay, of native HLZ and 
conjugates when stored at (A) room temperature (B) 50 °C (black = native enzyme; 
red = M-DTM conjugate; blue = alkyne-MAM conjugate; green = PEG-DTM 
conjugate; yellow = PEG-MAM conjugate). 
 
 
 
  
CONCLUSIONS 
 
In conclusion, enzyme conjugates have been synthesized by reacting 
dibromomaleimides and monobromomaleimides with reduced disulfides and free 
amines in human lysozyme and α-chymotrpysin. Reactions of dibromomaleimides 
with reduced disulfides produced dithiomaleimide bridged enzyme conjugates, which 
showed fluorescence upon formation. Both α-CT and HLZ DTM conjugates showed 
the same stability as the native enzyme when stored at room temperature, and 
exhibited negligible structural change by circular dichroism. However, at elevated 
temperature storage (50 °C) the HLZ DTM conjugates showed reduced stability, 
which corroborates a decrease in observed Tm, indicating this conjugation technique 
may have a de-stabilizing effect on some enzymes.  
Reactions of dibromo- and monobromomaleimides with free amines in both 
enzymes produced fluorescent aminobromo- and monoaminomaleimide conjugates 
respectively. Monoaminomaleimides are shown to react with higher efficiency in both 
enzymes and conjugates are shown to be as stable as native enzymes at room 
temperature and at 50 °C, however a decrease in Tm was observed by DSC. 
Fluorescence analysis of all conjugated enzymes showed excitation and emission 
profiles comparable to small molecule studies, however fluorescence quantum yields 
were low as a consequence of solvent quenching effects.  
Both reactions were trialed as PEGylation methods using bromomaleimide 
functionalized PEG. Conjugation efficiency was detrimentally effected, attributed to 
the reduced availability of chain ends and steric hindrance. While, the PEG-MAM 
HLZ conjugate showed marginally increased fluorescence quantum yield attributed 
to solvent shielding effects of the short PEG chain.  
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TABLES 
 
 
 
 
 
Table 1. Table showing number of attached units and conjugation efficiency for disulfide conjugates 
observed by MALDI-ToF and standard deviation measured by Gaussian fit. †= Gaussian fit not 
possible, observed conjugates listed. ‡= Quantification not possible. 
 
 
 
 
 
 
 
 
 
 
Table 2. Table showing number of attached units and conjugation efficiency for amine conjugations 
observed by MALDI-ToF and standard deviation measured by Gaussian fit. 
 
FIGURE LEDGENDS 
 
Figure 1: (A) Illustration of disulfide based bromomaleimide conjugations to α-CT 
and HLZ. (B) 2D excitation–emission spectra of M-DTM HLZ conjugate. MALDI-ToF 
mass spectra of (C) M-DTM α-CT conjugate (D) PEG-DTM α-CT conjugate (E) M-DTM 
HLZ conjugate (F) PEG-DTM HLZ conjugate (red) with the native enzyme (black). 
 
Figure 2: (A) Illustration of amine based bromomaleimide conjugations to α-CT and 
HLZ. (B) 2D excitation–emission spectra of alkyne-MAM HLZ conjugate. MALDI-ToF 
mass spectra of (C) alkyne-MAM α-CT conjugate (D) PEG-MAM α-CT conjugate (E) 
Enzyme Conjugate # Attached 
Conjugation 
efficiency 
α-CT 
M-DTM 3/5† 60 % 
PEG-DTM 1.8 ± 1.5/5 36 % 
HLZ 
M-DTM  0-4/4†   ‡ 
PEG-DTM 2.0 ± 1.8/4 50 % 
Enzyme Conjugate # Attached 
Conjugation 
efficiency 
α-CT 
M-ABM 6.2 ± 2.5/17 36 % 
M-MAM 12.1 ± 3.6/17 71 % 
Alkyne-MAM 11.2 ± 1.8/17 66 % 
PEG-MAM 2.3 ± 1.5/17 14 % 
HLZ 
M-ABM 2.7 ± 2.3/6 45 % 
M-MAM 5.4 ± 3.1/6 90 % 
Alkyne-MAM 4.9 ± 2.5/6 82 % 
PEG-MAM 1.5 ± 1.8/6 25 % 
alkyne-MAM HLZ conjugate (F) PEG-MAM HLZ conjugate (red) and the native 
enzyme (black). 
 
Figure 3: (A) Initial activity of α-CT at time points against purified conjugates at t = 
0 hr and (B) residual activities of native α-CT and conjugates (black = native 
enzyme; red = M-DTM conjugate; blue = alkyne-MAM conjugate; green = PEG-DTM 
conjugate; yellow = PEG-MAM conjugate). 
 
Figure 4: The residual activity, by EnzChek® lysis assay, of native HLZ and 
conjugates when stored at (A) room temperature (B) 50 °C (black = native enzyme; 
red = M-DTM conjugate; blue = alkyne-MAM conjugate; green = PEG-DTM 
conjugate; yellow = PEG-MAM conjugate). 
 
